Please use this identifier to cite or link to this item:
|Title:||Use of surodex in phacotrabeculectomy surgery||Authors:||Seah, S.K.L.
|Issue Date:||2005||Citation:||Seah, S.K.L., Husain, R., Lim, M.C.C., Hoh, S.-T., Oen, F.T.S., Aung, T., Gazzard, G. (2005). Use of surodex in phacotrabeculectomy surgery. American Journal of Ophthalmology 139 (5) : 927-928. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ajo.2004.10.052||Abstract:||PURPOSE: To evaluate the use of Surodex (Oculex Pharmaceuticals, Sunnyvale, California) a drug delivery system incorporating 60 micrograms of dexamethasone in a pellet, in phacotrabeculectomy surgery. DESIGN: Nonrandomized, prospective, interventional case series. METHODS: Phacotrabeculectomy was performed on 37 Asian subjects with primary open-angle glaucoma (POAG) using a standardized technique. All subjects received a Surodex pellet underneath the scleral flap. Results were compared with those of 31 POAG subjects who had undergone phacotrabeculectomy augmented with 50 mg/ml of intraoperative 5-fluorouracil (5-FU) during the same period. RESULTS: Mean follow-up in months was 19.7 ± 7.9 and 22.1 ± 6.2 for the Surodex and 5-FU groups, respectively (P = .29). There was a 20.1% decrease in intraocular pressure in the Surodex group compared with 28.5% decrease in the 5-FU group (P = .6). Postoperative complications occurred in three cases (8.1%) and six cases (19.3%), respectively (P = .04). CONCLUSIONS: Combined phacotrabeculectomy surgery augmented by intra-scleral placement of Surodex results in good control of IOP and a low incidence of complications. © 2005 by Elsevier Inc. All rights reserved.||Source Title:||American Journal of Ophthalmology||URI:||http://scholarbank.nus.edu.sg/handle/10635/29140||ISSN:||00029394||DOI:||10.1016/j.ajo.2004.10.052|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.